https://www.selleckchem.com/pr....oducts/pf-06650833.h
Nontargeted circulating tumor DNA (ctDNA) whole-genome sequencing is a novel strategy for genomic characterization of high-grade serous ovarian cancer. Changes in ctDNA levels are a sensitive indicator of disease burden with an average lead time of 6 months to clinical progression. This presents a unique opportunity to identify pathways driving progression as molecular vulnerabilities for clinical drug development.See related article by Paracchini et al., p. 2549.Genomic alterations in penile squamous cell carcinoma (PSCC) appear si
Aimer
Commentaire
Partagez
